Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Viktoria Odelga, MD, Jutta Ackermann, Verena Sagaster, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2007) 110 (11): 4845.

https://doi.org/10.1182/blood.V110.11.4845.4845

Published: 2007

Journal Articles

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andreas Chott, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2006) 108 (11): 2753.

https://doi.org/10.1182/blood.V108.11.2753.2753

Published: 2006

Journal Articles

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Johannes Drach, MD, Verena Sagaster, MD, Victoria Odelga, MD, Hannes Kaufmann, MD, Jutta Ackermann, Markus Galhuber, Niklas Zojer, MD, Elisabeth Küenburg, MD, Christoph Zielinski, MD, Rotraud Wieser, MD, Heinz Ludwig, MD

Blood (2006) 108 (11): 3398.

https://doi.org/10.1182/blood.V108.11.3398.3398

Published: 2006

Journal Articles

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Johannes Drach, MD, Sonja Seidl, MD, Oskar Pichelmayer, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2005) 106 (11): 4799.

https://doi.org/10.1182/blood.V106.11.4799.4799

Published: 2005

Journal Articles

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

Johannes Drach, MD, E. Kuenburg, MD, Verena Sagaster, MD, Niklas Zojer, MD, Hannes Kaufmann, MD, Jutta Ackermann, Heinz Ludwig, MD

Blood (2005) 106 (11): 509.

https://doi.org/10.1182/blood.V106.11.509.509

Published: 2005

Journal Articles

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Johannes Drach, MD, Jutta Ackermann, Catrin Baldia, MD, Hannes Kaufmann, MD, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Sonja Seidl, MD, Verena Sagaster, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ulrich Jaeger, MD, Christoph Zielinski, MD

Blood (2004) 104 (11): 4873.

https://doi.org/10.1182/blood.V104.11.4873.4873

Published: 2004

Journal Articles

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Hannes Kaufmann, MD, Catrin Baldia, MD, Jutta Ackermann, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Ulrich Jaeger, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ingrid Simonitsch-Klupp, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2004) 104 (11): 3459.

https://doi.org/10.1182/blood.V104.11.3459.3459

Published: 2004

NARROW

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis.

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma.

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Short Survival, Despite Promising Response Rates, after Bortezomib Treatment of Multiple Myeloma Patients with a 13q-Deletion.

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only